Recruiting PHASE1 INTERVENTIONAL 4-arm
NCT06581562
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. (IRIS-RD-01)
Sponsor: Artiva Biotherapeutics, Inc.
Conditions
Granulomatosis With Polyangiitis Pemphigus Vulgaris Rheumatoid Arthritis Systemic Lupus Erythematosus
Interventions
AB-101 Cyclophosphamide Fludarabine Rituximab
Updated 1 time since 2024 Last updated: Aug 29, 2024 Started: May 15, 2024 Primary completion: Jul 31, 2027 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Granulomatosis With Polyangiitis and Pemphigus Vulgaris and is currently actively recruiting participants. Artiva Biotherapeutics, Inc. leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Artiva Biotherapeutics, Inc.
- IRIS Research and Development, LLC
Data source: IRIS Research and Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .